Free Trial!
Today’s Best Stocks To Trade! Click Here
AirTran Holdings Inc. (NYSE: AAI | Quote | Chart | News | PowerRating) through its subsidiary, AirTran Airways, Inc., provides scheduled airline services in the United States. It operates scheduled airline service primarily in short-haul markets in the eastern United States, with flights originating and terminating at its hub in Atlanta, Georgia. As of January 23, 2008, the company operated 87 Boeing B717-200 and 50 Boeing B737-700 aircraft offering approximately 700 scheduled flights per day to 55 locations in the United States. AirTran Holdings serves its customers through the Internet, travel agencies, and its reservation call centers. The company was founded in 1992 and is headquartered in Orlando, Florida. With 92.3 million shares outstanding and 17.98 million shares declared short as of May 2008, there is no longer a failure to deliver in shares of AAI. According to quarterly data provided by the SEC, there were still 20,838 shares of AAI that were failing-to-deliver as of September 20, 2007.
Excel Maritime Carriers Ltd. (NYSE: EXM | Quote | Chart | News | PowerRating) a shipping company, engages in the ownership and operation of bulk carrier vessels. The company provides seaborne transportation services for dry bulk cargoes, such as iron ore, coal and grain, steel products, fertilizers, cement, bauxite, sugar, and scrap metal. As of May 15, 2008, its fleet consisted of 47 vessels comprising 4 Capesize, 14 Kamsarmax, 21 Panamax, 2 Supramax, and 6 Handymax with a total carrying capacity of approximately 3.7 million deadweight tonnage. The company was founded in 1988 and is headquartered in Hamilton, Bermuda. With 20.03 million shares outstanding and 3.27 million shares declared short as of May 2008, there is no longer a failure to deliver in shares of EXM. According to quarterly data provided by the SEC, there were still 54,630 shares of EXM that were failing-to-deliver as of September 28, 2007.
Tronox Inc. (NYSE: TRX | Quote | Chart | News | PowerRating) produces and markets titanium dioxide pigment in the United States and internationally. The company's titanium dioxide, a white pigment is used in a range of products for its ability to impart whiteness, brightness, and opacity. Its pigment product is used in coatings, plastics, and paper, as well as various specialty products, such as inks, food, and cosmetics. The company also offers electrolytic manganese dioxide, which is used as active cathode material for alkaline batteries; lithium manganese dioxide that is used as rechargeable battery material; sodium chlorate for the pulp and paper industry; boron trichloride, a specialty chemical gas, which is used in various products, including pharmaceuticals, semiconductors, high-performance fibers, specialty ceramics, and epoxies; and elemental boron that is used in igniter formulations for defense, pyrotechnic, and air bag industries. Tronox Incorporated was founded in 1964 and is based in Oklahoma City, Oklahoma. Tronox Inc. (NYSE:TRX) operates independently of Kerr-McGee Corp. as of March 30, 2006. With 41.63 million shares outstanding and 708,500 shares declared short as of May 2008, there is no longer a failure to deliver in shares of TRX. According to quarterly data provided by the SEC, there were still 10,800 shares of TRX that were failing-to-deliver as of September 20, 2007.
Acusphere Inc. (NASDAQ: ACUS | Quote | Chart | News | PowerRating) a specialty pharmaceutical company, develops new drugs and formulations of existing drugs using its proprietary porous microparticle technology in the United States. Its porous microparticle technology enables to control the size and porosity of particles, including nanoparticles and microparticles. The company develops products in the areas of cardiology, oncology, and asthma. Its lead product candidate Imagify, a cardiovascular drug is in Phase III clinical development for the detection of coronary artery disease. The company's products also include AI-850, a Phase I clinical trial completed product candidate that utilizes hydrophobic drug delivery system to improve the dissolution rate of a cancer drug; and AI-128, a Phase I clinical study completed formulation of asthma drug, which utilizes pulmonary drug delivery system. Acusphere has a license agreement with Cephalon, Inc. to provide license to Acusphere's Hydrophobic Drug Delivery System for oncology applications, along with the rights to AI-850, Acusphere's formulation of paclitaxel. The company was founded in 1993 and is headquartered in Watertown, Massachusetts. With 46.65 million shares outstanding and 682,700 shares declared short as of May 2008, there is no longer a failure to deliver in shares of ACUS. According to quarterly data provided by the SEC, there were still 18,708 shares of ACUS that were failing-to-deliver as of September 28, 2007.
Hudson Technologies Inc. (NASDAQ: HDSN | Quote | Chart | News | PowerRating) through its subsidiary, Hudson Technologies Company, provides various refrigerant products and services primarily to the commercial air conditioning, industrial processing, and refrigeration systems primarily in the United States. It offers RefrigerantSide services, including system decontamination to remove moisture, oils, and other contaminants, as well as predictive and diagnostic services; and refrigerant management services, which include reclamation of refrigerants, laboratory testing, storage services to individual customer requirements, and reusable cylinder repair and hydrostatic testing services. Hudson Technologies also sells reclaimed and virgin refrigerants to various customers in the air conditioning and refrigeration industry. The company serves commercial, industrial, and government customers, as well as refrigerant wholesalers, distributors, contractors, and refrigeration equipment manufacturers. Its industrial customers principally operate in petrochemical, pharmaceutical, industrial power, manufacturing, commercial facility, and property management and maritime industries. Hudson Technologies has a strategic alliance with The Linde Group to market its service offering outside the U.S. The company was founded in 1991 and is headquartered in Pearl River, New York. With 19.11 million shares outstanding and 16,300 shares declared short as of May 2008, there is no longer a failure to deliver in shares of HDSN.
Idenix Pharmaceuticals Inc. (NASDAQ: IDIX | Quote | Chart | News | PowerRating) a biopharmaceutical company, engages in the discovery and development of drugs for the treatment of human viral and other infectious diseases in the United States and Europe. It develops nucleoside/nucleotide polymerase inhibitors, including IDX102 and IDX184, which are in late-stage preclinical development; protease inhibitors; and non-nucleoside polymerase inhibitors for the treatment of hepatitis C virus. The company also develops IDX899 that has completed a phase I dose-escalation study for the treatment of HIV-1 from the class of compounds known as non-nucleoside reverse transcriptase inhibitors. In addition, Idenix Pharmaceuticals holds licenses for Tyzeka and Sebivo products for the treatment of patients with chronic hepatitis B. The company was founded in 1998 and is headquartered in Cambridge, Massachusetts. Idenix Pharmaceuticals, Inc. is a subsidiary of Novartis AG. With 56.34 million shares outstanding and 3.36 million shares declared short as of May 2008, there is no longer a failure to deliver in shares of IDIX. According to quarterly data provided by the SEC, there were still 15,957 shares of IDIX that were failing-to-deliver as of September 28, 2007.
About BUYINS.NET
WWW.BUYINS.NET is a service designed to help bonafide shareholders of publicly traded US companies fight naked short selling. Naked short selling is the illegal act of short selling a stock when no affirmative determination has been made to locate shares of the stock to hypothecate in connection with the short sale. Buyins.net has built a proprietary database that uses Threshold list feeds from NASDAQ, AMEX and NYSE to generate detailed and useful information to combat the naked short selling problem. For the first time, actual trade by trade data is available to the public that shows the attempted size, actual size, price and average value of short sales in stocks that have been shorted and naked shorted. This information is valuable in determining the precise point at which short sellers go out-of-the-money and start losing on their short and naked short trades.
BUYINS.NET has built a massive database that collects, analyzes and publishes a proprietary SqueezeTrigger for each stock that has been shorted, www.buyins.net/squeezetrigger.pdf. The SqueezeTrigger database of nearly 2,000,000,000 short sale transactions goes back to January 1, 2005, and calculates the exact price at which the Total Short Interest is short in each stock. This data was never before available prior to January 1, 2005, because the Self Regulatory Organizations (primary exchanges) guarded it aggressively. After the SEC passed Regulation SHO, exchanges were forced to allow data processors like Buyins.net to access the data.
The SqueezeTrigger database collects individual short trade data on over 7,000 NYSE, AMEX and NASDAQ stocks and general short trade data on nearly 8,000 OTCBB and PINKSHEET stocks. Each month the database grows by approximately 50,000,000 short sale transactions and provides investors with the knowledge necessary to time when to buy and sell stocks with outstanding short positions. By tracking the size and price of each month's short transactions, BUYINS.NET provides institutions, traders, analysts, journalists and individual investors the exact price point where short sellers start losing money.
All material herein was prepared by BUYINS.NET, based upon information believed to be reliable. The information contained herein is not guaranteed by BUYINS.NET to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. BUYINS.NET is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein. BUYINS.NET may receive compensation in cash or shares from independent third parties or from the companies mentioned.
BUYINS.NET affiliates, officers, directors and employees may also have bought or may buy the shares discussed in this opinion and may profit in the event those shares rise in value. Market commentary provided by Thomas Ronk.
BUYINS.NET will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission.
You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and BUYINS.NET undertakes no obligation to update such statements.
CONTACT: Thomas Ronk, CEO, BUYINS.NET Tel: +1 800 715 9999 e-mail: Tom@buyins.net WWW: http://www.buyins.net
M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.
More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index
About TradingMarkets | Contact | Advertise | Careers | Link to Us | Site Map | Help | Terms & Conditions | Privacy Policy | Return Policy | Testimonials | Feedback
